Charles N. York II Sells 4,370 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This represents a 1.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Day One Biopharmaceuticals Trading Up 1.6 %

NASDAQ:DAWN opened at $12.43 on Monday. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.13 and a twelve month high of $18.07. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. The stock has a fifty day simple moving average of $12.37 and a 200-day simple moving average of $13.48.

Wall Street Analysts Forecast Growth

DAWN has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $35.71.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after purchasing an additional 1,002 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Day One Biopharmaceuticals by 87.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,203 shares of the company’s stock worth $267,000 after purchasing an additional 8,935 shares during the last quarter. SteelPeak Wealth LLC lifted its position in shares of Day One Biopharmaceuticals by 9.8% during the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after purchasing an additional 1,550 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in shares of Day One Biopharmaceuticals by 8.2% during the third quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock worth $25,460,000 after purchasing an additional 139,160 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals during the third quarter worth $825,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.